SUBSCRIBE

WHO considers cost of cancer drugs and how to increase access

 Posted 11/01/2019

The increasing prices of cancer drugs is ‘impairing the capacity of healthcare systems to provide affordable, population-wide access to cancer medicines’, ac...

more
FDA releases guidances and proposed rule to adv... Guidelines | Posted 11/01/2019
EMA approval for bevacizumab biosimilar Zirabev Biosimilars/News | Posted 11/01/2019
Long-term follow-up of switching to biosimilar... Biosimilars/Research | Posted 11/01/2019
18794124_l
Trastuzumab and agalsidase beta biosimilars lau... Biosimilars/News | Posted 11/01/2019
Biosimilars makers in Canada to launch patient... Biosimilars/General | Posted 11/01/2019
Samsung BioLogics sues Korea’s FSC over account... Pharma News | Posted 11/01/2019
Sandoz to launch epinephrine in early 2019 at a... Generics/News | Posted 11/01/2019
WHO should finalize its BQ guidance Biosimilars/General | Posted 14/12/2018
International promotion and education for biosi... Reports | Posted 14/12/2018
British diabetologists issues position statemen... Biosimilars/General | Posted 14/12/2018
Biosimilars launched in the US at a significant... Biosimilars/News | Posted 14/12/2018
Five more countries added to EU-US mutual recog... Policies & Legislation | Posted 14/12/2018
Positive results for adalimumab and etanercept... Biosimilars/Research | Posted 14/12/2018
Health care in Iraq saves money by incorporatin... Pharma News | Posted 14/12/2018
FDA approves drug for cancers with specific bio... Generics/News | Posted 14/12/2018
International prescribing incentives for biosim... Reports | Posted 07/12/2018
FDA approves first rituximab biosimilar Truxima Biosimilars/News | Posted 07/12/2018
FDA issues post-CRL meeting guidance for generi... Guidelines | Posted 07/12/2018
Boehringer Ingelheim and Sandoz abandon biosimi... Biosimilars/General | Posted 07/12/2018
Positive results for Chinese rituximab and tras... Biosimilars/Research | Posted 07/12/2018
Way cleared in US for Suboxone and Zytiga generics Generics/General | Posted 07/12/2018
Positive phase I results for Fresenius Kabi’s p... Biosimilars/Research | Posted 07/12/2018
Glenmark gains FDA approval for MS and pneumoni... Generics/News | Posted 07/12/2018
International supply side policies for biosimilars Reports | Posted 30/11/2018
EC approval for pegfilgrastim biosimilars Pelme... Biosimilars/News | Posted 30/11/2018
Switching from reference products to biosimilar... Biosimilars/Research | Posted 30/11/2018
Effectiveness of chronic hepatitis C treatment... Generics/Research | Posted 30/11/2018
FDA approves more generics in 2018 than any oth... Generics/General | Posted 30/11/2018
Comparative results for CT-P10 in low-tumour bu... Biosimilars/Research | Posted 30/11/2018
Patient, health and trade groups say USMCA will... Policies & Legislation | Posted 30/11/2018
Alvotech makes deal with Fuji Pharma for biosim... Pharma News | Posted 30/11/2018
Access! 2019 AAM Annual Meeting Conferences | Posted 30/11/2018
International policies for interchangeability,... Reports | Posted 23/11/2018
Safety of originator and biosimilar epoetin alf... Biosimilars/Research | Posted 23/11/2018
Insulin glargine biosimilars launched in UK and... Biosimilars/News | Posted 23/11/2018
FDA strengthens and modernizes inspections for... Policies & Legislation | Posted 23/11/2018
22119008_l
AbbVie makes more deals delaying adalimumab bio... Pharma News | Posted 23/11/2018
Tanvex BioPharma submits filgrastim biosimilar... Biosimilars/News | Posted 23/11/2018
Positive phase III data for adalimumab biosimil... Biosimilars/Research | Posted 23/11/2018
Apotex having trouble with Competitive Generic... Generics/News | Posted 23/11/2018
Canadian report into international policies for... Reports | Posted 16/11/2018
Another adalimumab copy biological accepted for... Biosimilars/News | Posted 16/11/2018
Biosimilars makers in South Korea to benefit fr... Guidelines | Posted 16/11/2018
Higher generics use results in higher Medicare... Generics/Research | Posted 16/11/2018
20893354_l
Amgen collaborates with Orion to market Amgevit... Pharma News | Posted 16/11/2018
Generics companies winning the legal battle in... Generics/News | Posted 16/11/2018
Appeal by Australia’s watchdog against Pfizer r... Policies & Legislation | Posted 16/11/2018
Phase I study suggests similarity of omalizumab... Biosimilars/Research | Posted 16/11/2018
DIA Global Annual Meeting 2019 Conferences | Posted 16/11/2018
more

NON-BIOLOGICAL COMPLEX DRUGS

FDA issues final guidance on liposome drug products Posted 27/04/2018

On 4 April 2018, the US Food and Drug Administration (FDA) issued a new draft...

more


FDA approves 40 mg follow-on version of glatira... Non‐Biological Complex Drugs/News | Posted 09/03/2018
Mylan launches first follow-on glatiramer aceta... Non‐Biological Complex Drugs/News | Posted 15/02/2018
Biosimilars and follow-on NBCDs for MS in Europ... Non‐Biological Complex Drugs/Research | Posted 19/01/2018
Impax announces FDA approval of follow-on sevel... Non‐Biological Complex Drugs/News | Posted 17/11/2017
FDA approves follow-on version of sevelamer Non‐Biological Complex Drugs/News | Posted 30/06/2017
Challenges in the regulation of NBCDs Non‐Biological Complex Drugs/Research | Posted 12/05/2017
Scientific and regulatory considerations for fo... Non‐Biological Complex Drugs/Research | Posted 05/05/2017
Equivalence of complex drug products Non‐Biological Complex Drugs/Reports | Posted 14/04/2017
Follow-up studies needed to ensure safety for f... Non‐Biological Complex Drugs/Research | Posted 31/03/2017
Warning letter causes delays for follow-on glat... Non‐Biological Complex Drugs/News | Posted 17/03/2017
Is the EU ready for non-biological complex drug... Non‐Biological Complex Drugs/Research | Posted 03/03/2017
Follow-on versions of glatiramer acetate in Rus... Non‐Biological Complex Drugs/News | Posted 24/02/2017
Non-biological complex drugs and pharmacopoeias Non‐Biological Complex Drugs/Research | Posted 10/02/2017
In vitro analysis of follow-on versions of seve... Non‐Biological Complex Drugs/Research | Posted 18/11/2016
Determining the bioequivalence of follow-on iro... Non‐Biological Complex Drugs/Reports | Posted 04/11/2016
FDA to set up abbreviated pathway for complex p... Non‐Biological Complex Drugs/Polices & Legislation | Posted 21/10/2016
Challenges in the assessment of ophthalmic emul... Non‐Biological Complex Drugs/Reports | Posted 07/10/2016
Cancer lab to evaluate bioequivalence of nanosi... Non‐Biological Complex Drugs/News | Posted 23/09/2016
A conference on ‘Equivalence of Complex Drug Pr... Non‐Biological Complex Drugs/News | Posted 09/09/2016
Collaboration to introduce nanotechnologies in... Non‐Biological Complex Drugs/News | Posted 26/08/2016
Iron carbohydrate follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 12/08/2016
Rigorous approach used to approve a follow-on v... Non‐Biological Complex Drugs/Research | Posted 29/07/2016
US guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 10/06/2016
Non-biological complex drugs and their follow-o... Non‐Biological Complex Drugs/Research | Posted 03/06/2016
Is a new pathway for NBCDs on the way in the US? Non‐Biological Complex Drugs/Polices & Legislation | Posted 27/05/2016
Follow-on glatiramer acetate gains European app... Non‐Biological Complex Drugs/News | Posted 13/05/2016
FDA includes follow-on versions in its new cycl... Non‐Biological Complex Drugs/Guidelines | Posted 29/04/2016
Switching between originator and follow-on iron... Non‐Biological Complex Drugs/Research | Posted 22/04/2016
Follow-on intravenous iron formulations in haem... Non‐Biological Complex Drugs/Research | Posted 01/04/2016
Glatiramoid follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/03/2016
FDA includes follow-on versions in its new lipo... Non‐Biological Complex Drugs/Guidelines | Posted 26/02/2016
EU guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 22/01/2016
GDUFA regulatory priorities for 2016 include co... Non‐Biological Complex Drugs/Polices & Legislation | Posted 11/12/2015
Liposomal follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/12/2015
Regulations for follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 13/11/2015
Status and regulatory issues surrounding follow... Non‐Biological Complex Drugs/Reports | Posted 05/11/2015
Follow-on glatiramer acetate (M356) claimed as... Non‐Biological Complex Drugs/Research | Posted 05/11/2015
EMA issues reflection paper for follow-on versi... Non‐Biological Complex Drugs/Guidelines | Posted 05/11/2015
FDA approves first follow-on version of glatira... Non‐Biological Complex Drugs/News | Posted 05/11/2015
more

Country Focus

All countries

Sign up today to receive weekly news on the latest developments in generic and biosimilar medicines!

Generics News Research General

more

Biosimilars News Research General

more

More editorial sections